Stock Evaluator: Bio-Rad Laboratories, Inc. (BIO)

Bio-Rad Laboratories, Inc. BIO

$325.48 -1.24 -0.38%
July 31, 2026 4:00:03 PM EST November 10, 2021 Volume: 190,103
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NYSE | DELAYED PRICE
SECTOR INDUSTRY
Health Care Life Sciences Tools & Services

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Commentary & Analysis


Financial Summary

Share Statistics BIO Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $8,655.8 $1,774.7 75%
Shares Out (Mil) 27.0 94.8 35%
Institutional Ownership 46.0% 90.1% 20%
Float (Mil) 20.9 69.9 30%
Beta 1.08 1.20 65%
Avg Daily Volume (000s) 353 838 53%
Price Change
(52-week)
29.3% 81.0% 69%
Growth BIO Industry
Median
Percentile
(All Stocks)
Sales (5yr) 0.3% 7.8% 18%
Net Income (5yr) (27.6%) (13.7%) 15%
EPS (5yr) (26.1%) 0.7% 10
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) 59.5% (15.0%) 95%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 3 5 5
Current EPS $1.745 $9.002 $9.722
Month Ago EPS $1.745 $9.002 $9.722
# Rev Up 1 0 0
# Rev Down 0 2 1
Three Months Ago EPS $2.449 $10.260 $11.348
Year/Year Chg (108.9%) (67.7%) (64.8%)
Financials BIO Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $2,590 $763 64%
Net Income (TTM) (Mil) $169 ($14) 66%
EPS (TTM) $6.244 ($0.200) 90%
Operating Cash Flow (TTM) (Mil) $510 $53 72%
Net Cash Flow (TTM) (Mil) ($14) ($5) 29%
Long-Term Debt (Q1) (Mil) $942 $270 66%
Enterprise Value (Q1) (Mil) $8,481 $2,430 71%
Valuation BIO Industry
Median
Percentile
(All Stocks)
P/B 1.28 3.00 32%
P/E 52.4 43.5 85%
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 5.3 na
Ratios BIO Industry
Median
Percentile
(All Stocks)
Gross Margin 52.0% 47.6% 64%
Net Margin 6.5% (2.9%) 53%
ROA 1.7% (3.2%) 54%
ROE 2.5% (4.5%) 39%
Liabilities to Assets 30.0% 43.0% 21%
F-Score 7 5 84%

Bio-Rad Laboratories, Inc. did not pass any screens on 7/30/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors